Last updated 2026-06-18
- Raised $11.1M funding round, Dec 2023
- Raised $252k funding round, Oct 2023
- Raised $2.3M funding round, Sep 2021
Total raised
$13.6M
Last: 2023-12
Stage
Series A
Founded
2019
Headcount
20
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.
The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.
Funding history · 3 rounds · $13.6M total
2023-12
$11.1M
2023-10
2021-09
$2.3M
Q&A
- What is Edity Therapeutics' core technology?
- Edity Therapeutics is developing a platform that uses human immune cells to deliver therapeutic proteins directly to the cytoplasm of target cells, aiming to reprogram cells and tissue.
- When was Edity Therapeutics founded?
- Edity Therapeutics was founded in October 2019.
- How many employees does Edity Therapeutics currently have?
- Edity Therapeutics has 11-50 employees.
- What is the total amount of funding Edity Therapeutics has raised to date?
- Edity Therapeutics has raised a total of $13,632,300 USD.
- When did Edity Therapeutics complete its most recent funding round and who were the investors?
- Edity Therapeutics completed a funding round in December 2023, with Dr. Reddy's Laboratories participating.
- Which investors participated in Edity Therapeutics' September 2021 funding round?
- In September 2021, NFX Capital and Tal Ventures participated in a funding round for Edity Therapeutics.
- What is Edity Therapeutics' primary sector?
- Edity Therapeutics' primary sector is Health Tech & Life Sciences.
- Who are the co-founders of Edity Therapeutics?
- The co-founders of Edity Therapeutics are Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster.
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
drug-deliveryproteinsgene-editingbiotechnologygeneticsgenomicsgenetic-disordersoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | edity-tx.com |
|---|---|
| linkedin.com/company/67330457 | |
| YouTube | youtube.com/@editytherapeuticsltd.388 |
Identifiers & details
| Founded | 2019-10 |
|---|---|
| Employees (exact) | 20 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | edity-tx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|